Hi Win
In the scheme of things this isn't too bad.
It is interesting to note that Merrill Lynch have decreased their estimate of PNV's 2H revenue by 10% to compensate for the effects of Omicron.
They also say that an appropriate EV/Revenue multiple of 17x is applicable for a global high-growth small cap medical technology company.
If this multiple was applied to ARX over time (once the company has proved itself) there will be a significant upward rerating of the share price.
Hi WinIn the scheme of things this isn't too bad. It is...
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
0.010(2.00%) |
Mkt cap ! $175.5M | |||
| Open | High | Low | Value | Volume |
| 53.5¢ | 53.5¢ | 49.0¢ | $51.73K | 103.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 600 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 51.0¢ | 8870 | 2 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
50.0¢ |
Change
0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 52.5¢ | 53.5¢ | 48.5¢ | 60919 | ||
| Last updated 15.32pm 26/04/2024 ? | |||||
| ARX (ASX) Chart |